Offspring of rats with diabetes mellitus are at risk of reduced calcium and bone mineral content. Altered expression of the maternal calcium binding proteins, calbindin-D 9K and calbindin-D 28K , which are involved in renal and placental calcium transport, may underlie these problems.We have investigated the effect of diabetes on circulating concentrations of regulatory hormones with respect to calbindin-D mRNA concentrations. Three rat groups were studied; control (CP), streptozotocininduced diabetic (DP), and insulin-treated diabetic (DPI) pregnant rats. Calbindin-D 9K and calbindin-D 28K mRNA abundance in placenta and maternal kidney were measured at days 7, 15, 18 and 21 of gestation, together with serum or plasma concentrations of 1,25 dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), parathyroid hormone (PTH), PTH-related protein (PTHrP), calcitonin, oestradiol and IGF-I. An increase in placental calbindin-D 9K mRNA abundance between days 18 and 21 in CP and DPI rats was severely blunted in the DP rats. In contrast, renal calbindin-D 28K mRNA abundance was greater at days 7, 15 and 18 in DP compared with CP rats, as was calbindin-D 9K at day 18. Calcitonin concentrations showed no differences between the groups, and both PTH and IGF-I were reduced over the first half of gestation, unlike the calbindins. In contrast, the concentrations of PTHrP and 1,25(OH) 2 D 3 were reduced at term in the DP group compared with the other two groups. Plasma oestradiol concentrations were lower in DP than in CP rats at days 7, 15 and 18, and most striking was the absence in DP rats of the peak of oestradiol seen at day 18 in CP rats. Despite the similarity between changes in placental calbindin mRNA and 1,25(OH) 2 D 3 , previous work has shown placental calbindin-D 9K regulation to be vitamin-D-independent. These studies produce suggestive evidence, therefore, that PTHrP and oestradiol may be involved in the altered calbindin-D expression by kidney and placenta in rat diabetic pregnancy.
Introduction
Significant alterations in calcium homeostasis occur in up to 50% of infants born to insulin-dependent diabetic mothers (Tsang et al. 1972) . Such children have an increased incidence of hypocalcaemia (Tsang et al. 1972 , Mimouni et al. 1986 and either a decreased (Lapillone et al. 1997) or an increased (Mimouni et al. 1988) bone mineral content compared with normal infants. A reduced bone mineral content, retarded skeletal development, or both, is found in the offspring of genetically diabetic rats (Verhaeghe et al. 1988a ) and those rendered diabetic by streptozotocin (STZ; Uriu-Hare et al. 1985 , Demignon & Bonneton-Rebut 1988 . The reduced bone mineral content in the rat may be attributable in part to a reduced maternofetal placental calcium flux (Husain et al. 1994) , associated with an exacerbated maternal renal loss of calcium (Birdsey et al. 1995) .
Both placental and renal epithelia transport calcium by an energy-dependent transcellular process (Shareghi & Stoner 1978 , S {tulc & S {tulcová 1986 . In pregnancy, the expression of the cytosolic calcium binding protein, calbindin-D 9K , appears to be rate-limiting to transcellular calcium transport across the rat placenta (Glazier et al. 1992) . In diabetic rat pregnancy, the abundance of placental calbindin-D 9K mRNA is markedly reduced near term, in association with a diminished maternofetal calcium flux (Husain et al. 1994) . In the kidney, the energy-dependent component of calcium reabsorption occurs mainly in the distal tubule and involves another cytosolic transporting protein, calbindin-D 28K (the main renal protein) in addition to calbindin-D 9K (Thomasset et al. 1982) . One study has reported that maternal renal concentrations of calbindin-D 9K and calbindin-D 28K proteins at term were comparable between control and genetically diabetic rats (Verhaeghe et al. 1988b) . The regulation of expression of calbindins in these two calcium-transporting epithelia is distinct: whereas renal calbindin expression is dependent on serum vitamin D 3 metabolite concentrations (Thomasset et al. 1982) , placental calbindin-D 9K expression is apparently not regulated by this hormone (Glazier et al. 1995) .
Altered placental and renal calcium handling in rat diabetic pregnancy may, at least in part, reflect an altered production or function of calcium regulatory hormones. However, it is not known when, in the course of pregnancy, the effect of diabetes on placental and renal calbindin expression manifests itself, nor how this relates to pregnancy and to diabetes-dependent changes in circulating hormones. The aim of this study was to address these questions by measuring calbindin-D 9K and calbindin-D 28K mRNA expression in placenta and kidney over the course of pregnancy in control, diabetic, and insulintreated diabetic rats. In the same animals, we also measured maternal serum or plasma concentrations of hormones associated with calcium homeostasis (1,25 dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), parathyroid hormone (PTH), PTH-related protein (PTHrP) and calcitonin), and those likely to change in diabetes (insulin-like growth factor-I (IGF-I)) or pregnancy (oestradiol). Most of these hormones have also been shown to be putative controllers of calbindin-D expression. It is well known that both renal calbindins are vitamin-D-dependent (Thomasset et al. 1982) . Both the placental calbindin-D 9K gene (Darwish et al. 1991) and the renal calbindin-D 28K gene (Gill & Christakos 1995) have been shown to have an oestrogen-responsive element. Although the geneexpression effects of both PTH and PTHrP are unknown, PTH has been shown to increase cytosolic concentration of renal calbindin-D 28K in vivo (Hemmingsen et al. 1996) , whereas PTHrP has been shown to increase renal calbindin-D 28K in the rat by a direct effect, without mediation by 1,25(OH) 2 D 3 or plasma calcium (Hemmingsen et al. 1996) . We hypothesised that a temporal association between altered calbindin-D expression and an alteration in one or more of the hormones measured would provide clues to the mechanisms responsible for the altered calcium handling by placenta and kidney associated with diabetic pregnancy in the rat.
Materials and Methods

Animals
All work was performed in accordance with the UK Animals (Scientific Procedures) Act 1986. Female Sprague-Dawley rats (Charles River Laboratories, Wilmington, Kent, UK) weighing approximately 210 g at the start of the experiment were used. Animals were housed in individual wire-bottomed cages and exposed to a 12 h light:12 h darkness cycle in a temperature controlled room (21-23 C). Animals had commercial rat chow (CRM, Labsure, Poole, Dorset, UK) and tap water available ad libitum throughout the study. Three animal groups were studied.
Diabetic pregnant rats (group DP) Female rats aged 8 weeks were rendered diabetic by an i.p. injection of 60 mg/kg STZ (Sigma, Poole, Dorset, UK). This was freshly dissolved in ice-cold 0·1 M citrate buffer (pH 4·8) as detailed previously (Birdsey et al. 1995) . Diabetes mellitus was confirmed 2 days later by the development of glycosuria (Labstix, Ames, Slough, Berks, UK) and hyperglycaemia (blood glucose concentration >15 mM). Blood for the latter measurement was obtained by needle puncture of a tail vein and assayed using a blood glucose analyser (HemoCue Ltd, Sheffield, Yorks, UK). Any rat with a blood glucose concentration <15 mM was excluded from the study at this stage. Three days later, each female diabetic rat was housed with a nondiabetic male rat for mating. The day on which a vaginal copulation plug was found was designated day 1 of gestation (term=22-23 days).
Control pregnant rats (group CP) Control female animals received an i.p. injection of citrate buffer alone and were subsequently mated as described above.
Insulin-treated diabetic pregnant rats (group DPI)
These rats were rendered diabetic as described above. Immediately after confirmation of diabetes, each animal received one interscapular s.c. 10% porcine insulin implant (LinShin Canada Inc., Toronto, Canada) under halothane anaesthesia, in order to maintain a blood glucose concentration less than 10 mM. Insulin-treated rats were then allowed to mate as above. Maternal tail-vein blood glucose concentrations were monitored at 2-day intervals throughout gestation (HemoCue Ltd) and further insulin implants were given as appropriate to control glycaemia; each implant lasted approximately 10 days. As a control measure, some of the DP and CP group rats (see above) were given placebo implants. These had no effect on their blood glucose concentrations or any other variables. Data from DP and CP group animals with and without placebo implants were therefore pooled.
Blood and tissue collection
Animals were killed by cervical dislocation at day 7, 15, 18 or 21 of gestation. After immediate laparotomy, the terminal blood sample was withdrawn from the abdominal aorta and an aliquot immediately placed in a heparinised tube for plasma separation. Other blood aliquots were handled appropriately for specific hormone analysis (see below). Both kidneys and all placentas were removed, briefly blotted and immediately frozen in liquid nitrogen. All tissues were stored at 80 C.
Plasma was assayed for glucose concentration by the glucose oxidase-peroxidase method (Ames Sera-Pak, Bayer Diagnostics, Basingstoke, Hampshire, UK). Incubated samples were measured on a spectrophotometer (Shimadzu UV2101PC, Shimadzu Corp., Kyoto, Japan) at a wavelength of 505 nm.
RNA extraction and Northern/dot blot analysis
Tissue was used from six to eight rats randomly chosen from each experimental group at each gestational sample time (except for day 7, when the chorioallantoic placenta is not fully formed). Total RNA was extracted from placentas (ten on day 15, four or five on day 18, and three on day 21 from each rat, again using random sampling) and one kidney (left or right, alternate sampling), as described previously (Glazier et al. 1992) . The resulting RNA pellet was dissolved in RNase-free water, quantified by measuring absorbance at 260 nm and then stored at 80 C. Sets of dot blots of all placental and all kidney RNA were prepared using 20 mg total RNA from each tissue sample, incubated with 10 standard saline citrate (SSC) and 50% formamide at 60 C for 10 min. The sample was applied to a filter (Hybond N, Amersham International, Bucks, UK), washed twice with 10 SSC and fixed by exposure to u.v. light.
We have previously shown that the calbindin-D 9K cDNA used here detected a single transcript of the expected size (0·6 kb) on Northern blots of placental mRNA (Glazier et al. 1992 (Glazier et al. , 1995 . To check the size of the renal calbindin-D 9K and calbindin-D 28K transcripts, a pool of poly-A enriched RNA (Pharmacia Biotech, St Albans, UK) was prepared from kidneys of the CP and DP groups at each gestational age and Northern blots prepared as described previously (Glazier et al. 1992 ).
Filters were prehybridised, then hybridised with 32 Plabelled cDNA for either rat intestinal calbindin-D 9K (placenta and kidney) or calbindin-D 28K (kidney only) as described previously (Thomasset et al. 1982 , Lomri et al. 1989 , with the addition, at the end of the previous method, of two stringency washes (0·1 SSC, 0·1% SDS at 60 C for 20 min) for calbindin-D 28K hybridisations.
Replicates of all dot blots were probed with oligo-dT as a control to correct for variations in loading between samples. All blots were analysed and dot blots quantified on an autoimager (Packard Instant Imager, Packard Bioscience, Berks, UK) for varying times, depending on the strength of the signal (2 min for oligo-dT, up to 3 days for the calbindin-D 9K Northern blot). The Instant Imager provides a visual image of the signal and quantitates it by measuring radioactive emission with a wide dynamic range. Northern blots were also autoradiographed at 80 C.
Measurements on terminal blood samples
1,25(OH) 2 D 3 A 1 ml aliquot of blood was placed in a lithium-coated tube and the plasma separated by centrifugation. Plasma 1,25(OH) 2 D 3 concentration was measured using a kit (IDS Ltd, Boldon, Tyne and Wear, UK), which involved immunoextraction followed by radioimmunoassay as described previously (Fraser et al. 1997) . The inter-and intra-assay variations were 8% and 10% respectively, and the assay sensitivity was 5 pM.
PTH To obtain serum, 1 ml blood was allowed to clot and then centrifuged. PTH concentration was determined in duplicate using a Rat PTH Immunoradiometric Assay kit (Nichols Diagnostics, Cambridge, UK). Intra-assay variation was 4-4·3%, inter-assay variation 4·3-4·7% and assay sensitivity was 1 pg/ml (data provided by the suppliers).
PTHrP One millilitre of blood was dispensed into an ice-cold PTHrP cocktail tube (Nichols Diagnostics). The sample was centrifuged and the plasma used for determination of PTHrP (in duplicate) using the Allegro PTHrP Immunoradiometric Assay (Nichols Diagnostics). The supplier reported that this assay had a sensitivity of 0·3 pM, an intra-assay variation of 2·9-9·5% and an inter-assay variation of 5·3-5·6%. The validity of using this kit for rat measurements has been confirmed (Benitez-Verguizas & Esbrit 1994 , Naranjo et al. 1994 ).
Calcitonin Calcitonin concentration was determined in duplicate serum samples using a Calcitonin Chemiluminescence Immunoassay kit (Nichols Diagnostics). Intra-assay variation was 6·7-8·3%, inter-assay variation was 6·6-11·6%, and assay sensitivity was 3-5 pg/ml as reported by the suppliers. The validity of using this kit for rat measurements has been confirmed (Kalu et al. 1988) .
Oestradiol Oestradiol concentration in duplicate 100 µl serum samples was determined using a Coat-A Count Oestradiol radioimmunoassay kit (DPC Limited, Gwynedd, UK). Intra-assay variation was 4-7%, interassay variation 4·2-8·1% and assay sensitivity 8 pg/ml as reported by the suppliers.
IGF-I IGF-I was measured in duplicate 200 µl serum samples using an IGF-I Immunoassay kit (Nichols Diagnostics). Assay sensitivity was 0·1 ng/ml as reported by the suppliers. Intra-assay variability was 2·4-3%, the inter-assay coefficient of variation was 5·2-8·4%.
Statistics
All data are presented as means .., and n=number of animals. A two-way analysis of variance (ANOVA) was first performed, including the Bartlett-Box test for the homogeneity of variances between the groups. If variances were not significantly different, a one-way ANOVA with Scheffé's post hoc test was performed at each gestational time point, to distinguish differences between the three groups. If variances were significantly different, the nonparametric Kruskall-Wallis test was used, followed by paired Mann-Whitney U-tests for specific differences between the groups. Any further specific post hoc tests (a decrease or increase in values) were performed using an unpaired Student's t-test.
Results
Plasma glucose
Plasma glucose concentrations in terminal blood samples for the DP group were significantly greater than those in the CP and DPI groups at each gestational time point (Fig. 1) . Plasma glucose concentrations in the DPI rats were comparable to those in the CP group, except at day 7, when DPI values were slightly but significantly (P<0·01) lower.
Gestational changes in placental and renal calbindins
We have previously shown, by Northern blotting, that probing of placental mRNA with the calbindin-D 9K cDNA gives a single transcript of 0·6 kb, as expected (Glazier et al. 1992 , Husain et al. 1994 . Figure 2a shows data from placental dot blots probed with calbindin-D 9K cDNA, normalised to oligo-dT concentrations. In CP animals, a large and significant (P<0·01, t-test between CP day 18 and CP day 21) increase in the abundance of calbindin-D 9K mRNA was apparent over the last 3 days of gestation. This increase was severely attenuated by day 21 in the DP group (P<0·001 comparing CP and DP animals). The insulin-treated group showed a pattern similar to that of the CP group, with a sharp increase in calbindin-D 9K mRNA between days 18 and 21, to values intermediate between those in the other two groups -that is, DPI calbindin-D 9K mRNA expression was significantly lower than in CP and higher than in DP groups at day 21. Some fluctuations earlier in gestation meant that calbindin-D 9K mRNA in the insulin-treated group was lower than that in the CP group at days 15 and 18, and lower than that in the DP group at day 15. However, the major change in calbindin-D 9K mRNA expression from day 18 to day 21 was comparable between the CP and DPI groups (3·7-fold and 5·7-fold respectively), but was lower (only 2·4-fold) in the DP group. Northern hybridisation of renal poly-A-enriched RNA (from CP and DP rats) with calbindin-D 9K cDNA revealed a single transcript at 0·6 kb in both the CP and DP groups (Fig. 3a) , consistent with previous observations (Huang et al. 1989 , Li & Christakos 1991 . Quantitation of renal calbindin-D 9K mRNA in dot blots, normalised to oligo-dT, is shown in Fig. 2b . In CP animals, calbindin-D 9K mRNA levels remained steady until day 18 of gestation, after which there was a sharp increase (P<0·02, comparing days 18 and 21 by t-test). In contrast to the pattern seen in the placenta, renal calbindin-D 9K mRNA in diabetic animals was higher than in either the CP or DPI groups throughout gestation. However, this achieved statistical significance only at day 18 (P<0·001 DP compared with CP; P<0·01 DP compared with DPI, one-way ANOVA). At term, no differences existed between the three groups. This was due primarily to the increase in calbindin-D 9K mRNA in the CP group, rather than a decrease in the values in DP animals.
Northern hybridisation of rat renal poly-A RNA with calbindin-D 28K cDNA (Fig. 3b ) revealed three transcripts, at 3·3, 2·8 and 1·9 kb, which agrees well with previous reports (Huang & Christakos 1988 , Huang et al. 1989 . All three transcripts on the Northern blot appeared to change similarly over gestation and to have greater expression in the DP group than in the CP group. This was confirmed when quantification of the dot blot was performed (Fig. 2c) . In CP kidneys, there was a trend in calbindin-D 28K mRNA expression similar to that seen for calbindin-D 9K , with mRNA levels remaining relatively low until day 18, after which a sharp increase occurred to day 21 (P<0·05, comparing days 18 and 21 by t-test). Again, calbindin-D 28K mRNA levels in DP kidneys were greater (P<0·01, Mann-Whitney U-test) than in those of the CP animals throughout gestation until day 21. As for Figure 1 Plasma glucose concentrations from the terminal sample taken at days 7, 15, 18 and 21 of gestation in CP (, n=15, 9, 9, 8) , DP (, n=14, 9, 8, 14) and DPI (, n=11, 9, 7, 9) rats. **P<0·01, ***P<0·001 compared with CP and DPI; ++P<0·01 compared with DPI (Mann-Whitney U-tests). Values are means S.E.M.
calbindin-D 9K , the DPI kidneys were intermediate between the other two groups, and showed a gestational pattern in mRNA expression similar to that seen in the CP group. 1,25(OH) 2 D 3 (Fig. 4a ) Maternal plasma concentrations of 1,25(OH) 2 D 3 remained relatively stable in both the CP and DPI groups until day 18 of gestation, when there was a marked, significant increase (P<0·01 for both groups, Mann-Whitney U-test). In the diabetic animals the concentration of 1,25(OH) 2 D 3 was significantly (P<0·05) lower than that in the CP and DPI animals at day 15, and failed to show the increase seen in the other two groups towards term. Fig. 4b) Maternal serum PTH concentrations differed between the three groups early in gestation. In particular, values for the DP group were significantly (P<0·001) lower than the CP group at day 7. Toward the end of gestation (days 18 and 21), no significant differences were apparent between the groups, and there was a consistent increase over the last 3 days of gestation in all groups. Fig. 4c ) DP animals showed a steady decrease in PTHrP concentrations from day 7 of pregnancy and, as a result, both the CP and DPI groups had significantly greater serum PTHrP concentrations than the DP animals at days 18 and 21 of gestation. This contrasts with the data for PTH, for which no significant differences were seen between groups at these stages. The value in the DPI group was significantly greater than those in the other two groups at day 15.
Gestational changes in maternal hormone concentrations
PTH (
PTHrP (
Calcitonin There was a decrease in calcitonin concentrations in each group as gestation proceeded, but no statistically significant differences were apparent between the three rat groups at any stage of gestation (data not shown). Fig. 4d) Maternal serum oestradiol concentrations in CP animals were greatest at day 18 of gestation, with a sharp decrease towards term. In contrast, in the DP group oestradiol concentrations decreased steadily throughout gestation and were lower than in controls until term, although this achieved significance only at day 18 (P<0·01 CP compared with DP, Mann-Whitney U-test). In the DPI rats, oestradiol concentrations were also greater than in the DP group until day 18, when values decreased sharply, to become lower than in either of the other groups. It is striking that both the DP and DPI groups failed to show the late gestational peak in oestradiol concentration that was evident at day 18 in CP rats. (, n=8, 8, 8) , DP (, n=8, 8, 8) and DPI (, n=8, 7, 8) rats. **P<0·01 compared with CP and DP; +P<0·05, ++P<0·01, +++P<0·001 compared with CP; ##P<0·01 compared with DPI (Mann-Whitney U-tests). Values are means S.E.M. (b) Ratio of renal calbindin-D 9K mRNA to oligo-dT at days 7, 15, 18 and 21 of gestation in CP (, n=6, 6, 6, 6) , DP (, n=6, 6, 6, 6) and DPI (, n=6, 6, 6, 6) rats. ***P<0·001 compared with CP; +P<0·05 compared with DPI (one-way ANOVA plus Scheffé's test). Values are means S.E.M. (c) Ratio of renal calbindin-D 28K mRNA to oligo-dT at days 7, 15, 18 and 21 of gestation in CP (, n=6, 6, 6, 6) , DP (, n=6, 6, 6, 6) and DPI (, n=6, 6, 6, 6) rats. **P<0·01 compared with CP; +P<0·05, ++P<0·01 compared with DPI (Mann-Whitney U-tests). Values are means S.E.M. Fig. 4e ) Maternal serum IGF-I concentrations showed a marked gestational decrease in all groups. The DP animals had a greatly reduced serum IGF-I concentration compared with both CP and DPI rats early in pregnancy (P<0·001 at days 7 and 15, Mann-Whitney U-test). Towards term, hormone concentrations in the three groups of animals began to converge, and by day 21 there was no significant difference between the groups.
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Discussion
Gestational changes in placental and renal calbindins
Over the last third of normal pregnancy, the rat fetus accumulates more than 99% of its body calcium (Comar 1956) . During this time, the unidirectional maternofetal placental calcium transfer increases markedly and approaches net flux (Glazier et al. 1992 (Glazier et al. , S {tulc & S {tulcová 1986 . This is normally matched by a gestational increase in placental calbindin-D 9K mRNA expression (current data and Glazier et al. 1992 , Krisinger et al. 1992 , suggesting that this protein is rate-limiting to placental calcium transport in the rat. Here, we report a progressively blunted gestational increase in placental calbindin-D 9K mRNA expression in the diabetic pregnant rat, complementing previous data showing a reduction at term (Husain et al. 1994 , Verhaeghe et al. 1988b . The diminished increase in placental calbindin-D 9K mRNA expression in diabetic animals that we observed from day 18 of pregnancy correlates with the diminished maternofetal placental calcium flux and lower fetal calcium content previously observed in these animals (Husain et al. 1994) .
In normal pregnancy, the increased fetal requirement for calcium as gestation proceeds places an increasing demand on maternal calcium homeostasis, although maternal plasma calcium concentrations are maintained in the rat towards term (Green & Hatton 1988 , Husain et al. 1994 and bone calcium stores are not depleted (Miller et al. 1986) . One possible mechanism whereby the non-diabetic mother might increase dietary calcium availability for the fetus is to limit renal losses by increasing renal calcium reabsorption. Indeed, previous reports from our laboratory have shown that there is a slight decrease in maternal renal calcium excretion towards the end of pregnancy (Birdsey et al. 1995 , Garland et al. 1997 . This may result, at least partially, from the sharp increase we have observed here in the expression of both calbindin-D species in the maternal kidney over days 18-21 of gestation. Such an increase would serve to enhance maternal renal calcium reabsorption in the distal tubule, thereby making more calcium available to the mother.
The novel longitudinal design of our study showed that renal calbindin-D mRNA expression was greatly increased in diabetic pregnant rats, compared with control values, up to day 18 of gestation. Our findings, at term, that maternal renal abundance of calbindin-D 9K and calbindin-D 28K mRNA were comparable between control and diabetic rats agree well with previous observations (Verhaeghe et al. 1988b) . The fact that renal calbindin mRNA abundance is high at the start of diabetic pregnancy may be interpreted as an adaptive response to the extremely high renal calcium output that occurs immediately after the onset of experimental diabetes (Anwana 1989 , Birdsey et al. 1995 . It is, perhaps, surprising that this is not further enhanced as the increased calcium demands (, n=12, 7, 7, 9) , DP (, n=11, 9, 10, 10) and DPI (, n=8, 8, 8, 8) rats. +P<0·05, ++P<0·01 compared with DPI; #P<0·05 compared with CP and DPI; **P<0·01, ***P<0·001 compared with DP (Mann-Whitney U-tests). Values are means S.E.M. (b) Maternal serum PTH at days 7, 15, 18 and 21 of gestation in CP (, n=9, 10, 9, 9) , DP (, n=10, 10, 12, 12) and DPI (, n=7, 8, 7, 8) rats. +P<0·05, +++P<0·001 compared with CP; *P<0·05 compared with CP and DPI (Mann-Whitney U-tests). Values are means S.E.M. (c) Maternal serum PTHrP at days 7, 15, 18 and 21 of gestation in CP (, n=8, 7, 6, 7) , DP (, n=9, 11, 9, 10) and DPI (, n=10, 8, 7, 8) rats. +P<0·05, ++P<0·01 compared with DPI; *P<0·05, **P<0·01, ***P<0·001 compared with DP (Mann-Whitney U-tests at day 15, one-way ANOVA at days 18 and 21). Values are means S.E.M. (d) Maternal serum oestradiol at days 7, 15, 18 and 21 of gestation in CP (, n=7, 8, 9, 7) , DP (, n=9, 7, 7, 10) and DPI (, n=8, 8, 7, 5) rats. +P<0·05, ++P<0·01 compared with DP; *P<0·05, **P<0·01 compared with DPI (Mann-Whitney U-tests). Values are means S.E.M. (e) Maternal serum IGF-I at days 7, 15, 18 and 21 of gestation in CP (, n=9, 9, 8, 8) , DP (, n=11, 11, 11, 12) and DPI (, n=6, 8, 7, 6) rats. +++P<0·001 compared with DP; *P<0·05, **P<0·01 compared with CP (Mann-Whitney U-tests). Values are means S.E.M.
IGF-I
The sharp decline in maternal serum IGF-I concentrations from approximately half-way through normal pregnancy is in accordance with earlier observations in the rat (e.g. Gargosky et al. 1990 ). Reduced serum IGF-I concentrations in diabetic pregnancy, as here in the rat, have previously been reported in humans (Whittaker et al. 1990 ) and rabbits (D'Ercole et al. 1984) . As the gestational profiles for IGF-I and calbindin-D mRNA levels were so dissimilar, it seems unlikely that IGF-I contributes to the altered calbindin-D mRNA expression of DP rats.
Calbindin mRNA expression, diabetes and hormonal control
This study underscores the likely importance of interplay between regulatory factors of gene expression for calbindin-D 28K and calbindin-D 9K in the kidney and placenta in response to maternal diabetes. Our data pinpoint gestational day 18 as a likely time of control of calbindin-D expression in both kidney and placenta, and its alteration in diabetes. The current study, with previous work, points to an effect of diabetic pregnancy on oestradiol and PTHrP concentrations as being key to the altered renal and placental expression of calbindin mRNA and, thus, the derangement in calcium handling by these organs in this condition.
